Company logo

ANVS - Annovis Bio, Inc.

NYSE -> Healthcare -> Biotechnology
Berwyn, United States
Type: Equity

ANVS price evolution
ANVS
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $6.35 $15.72 $16.76 $28.38
Short term investments
Net receivables
Inventory
Total current assets $10.22 $22.82 $25.55 $36.02
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $10.22 $22.82 $25.55 $36.02
Current liabilities
Accounts payable $1.93 $1.17 $4.15 $3.96
Deferred revenue
Short long term debt
Total current liabilities $3.56 $2.07 $5.41 $7.7
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $3.56 $2.07 $5.41 $7.7
Shareholders' equity
Retained earnings -$88.05 -$73.33 -$63.79 -$54.05
Other shareholder equity
Total shareholder equity $6.66 $20.74 $20.14 $28.32
(in millions $) 31 Jan 2023 31 Dec 2021 30 Jan 2021 30 Jan 2020
Current assets
Cash $28.38 $45.69 $8.07 $0
Short term investments
Net receivables $0.74
Inventory
Total current assets $36.02 $46 $8.12 $0.75
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets $0.37
Total investments
Total assets $36.02 $46 $8.12 $1.12
Current liabilities
Accounts payable $3.96 $0.69 $0.34 $1.23
Deferred revenue
Short long term debt
Total current liabilities $7.7 $1.51 $0.58 $2.01
Long term debt $0.5
Total noncurrent liabilities $7.68
Total debt $0.5
Total liabilities $7.7 $1.51 $0.58 $9.69
Shareholders' equity
Retained earnings -$54.05 -$28.73 -$14.24 -$8.78
Other shareholder equity $0
Total shareholder equity $28.32 $44.49 $7.54 -$8.58
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $13.84 $8.26 $7.79 $1.58
Selling, general & administrative $1.03 $1.5 $2.18 $1.59
Total operating expenses $14.86 $9.76 $9.97 $3.17
Operating income -$14.86 -$9.76 -$9.97 -$3.17
Income from continuing operations
EBIT -$14.72 -$9.54 -$9.74 -$3.09
Income tax expense
Interest expense
Net income
Net income -$14.72 -$9.54 -$9.74 -$3.09
Income (for common shares) -$14.72 -$9.54 -$9.74 -$3.09
(in millions $) 31 Dec 2022 31 Dec 2021 30 Jan 2021 30 Jan 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $16.52 $8.48
Selling, general & administrative $9 $6.06
Total operating expenses $25.51 $14.54 $6.64 $1.61
Operating income -$25.51 -$14.54 -$6.64 -$1.61
Income from continuing operations
EBIT -$25.33 -$14.49
Income tax expense
Interest expense
Net income
Net income -$25.33 -$14.49 -$5.46 -$0.99
Income (for common shares) -$25.33 -$14.49
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$14.72 -$9.54 -$9.74 -$3.09
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $0.63 $1.57 $1.54 $1.46
Total cash flows from operations -$9.37 -$9.61 -$11.63 -$3.61
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $8.57 $0.01
Net borrowings
Total cash flows from financing $8.57 $0.01
Effect of exchange rate
Change in cash and equivalents -$9.37 -$1.03 -$11.62 -$3.61
(in millions $) 31 Dec 2022 31 Dec 2021 30 Jan 2021 30 Jan 2020
Net income -$25.33 -$14.49 -$5.46 -$0.99
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $9.15 $4.7
Total cash flows from operations -$17.31 -$9.13 -$3.97 -$0.48
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $0 $46.74
Net borrowings
Total cash flows from financing $0 $46.74 $12.04 $0.44
Effect of exchange rate
Change in cash and equivalents -$17.31 $37.61 $8.07 -$0.03
Fundamentals
Market cap $107.22M
Enterprise value $100.86M
Shares outstanding 9.01M
Revenue $0.00
EBITDA -$37.09M
EBIT -$37.09M
Net Income -$37.09M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -2.89
EV/Sales N/A
EV/EBITDA -2.72
EV/EBIT -2.72
P/S ratio N/A
P/B ratio 16.10
Book/Share 0.74
Cash/Share 0.71
EPS -$4.12
ROA -156.80%
ROE -195.55%
Debt/Equity 0.27
Net debt/EBITDA 0.08
Current ratio 2.87
Quick ratio 2.87